Targeted inhibition of activin receptor-like kinase 5 signaling attenuates cardiac dysfunction following myocardial infarction

被引:93
|
作者
Tan, Sih Min [1 ]
Zhang, Yuan [1 ]
Connelly, Kim A. [1 ,3 ]
Gilbert, Richard E. [1 ,3 ]
Kelly, Darren J. [1 ,2 ]
机构
[1] Univ Melbourne, Dept Med, St Vincents Hosp, Fitzroy, Vic 3065, Australia
[2] St Vincents Inst Med Res, Melbourne, Vic, Australia
[3] Univ Toronto, St Michaels Hosp, Dept Med, Toronto, ON M5B 1W8, Canada
基金
英国医学研究理事会;
关键词
interstitial fibrosis; cardiac remodeling; heart failure; SMOOTH MUSCLE ACTIN; DIASTOLIC DYSFUNCTION; ANGIOTENSIN-II; FIBROSIS; TISSUE; INJURY; HEART; MYOFIBROBLASTS; HYPERTROPHY; TRANSITION;
D O I
10.1152/ajpheart.01048.2009
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Tan SM, Zhang Y, Connelly KA, Gilbert RE, Kelly DJ. Targeted inhibition of activin receptor-like kinase 5 signaling attenuates cardiac dysfunction following myocardial infarction. Am J Physiol Heart Circ Physiol 298: H1415-H1425, 2010. First published February 12, 2010; doi:10.1152/ajpheart.01048.2009.-Following myocardial infarction (MI), the heart undergoes a pathological process known as remodeling, which in many instances results in cardiac dysfunction and ultimately heart failure and death. Transforming growth factor-beta (TGF-beta) is a key mediator in the pathogenesis of cardiac remodeling following MI. We thus aimed to inhibit TGF-beta signaling using a novel orally active TGF-beta type I receptor [activin receptor-like kinase 5 (ALK5)] inhibitor (GW788388) to attenuate left ventricular remodeling and cardiac dysfunction in a rat model of MI. Sprague-Dawley rats underwent left anterior descending coronary artery ligation to induce experimental MI and then were randomized to receive GW788388 at a dosage of 50 mg . kg(-1) . day(-1) or vehicle 1 wk after surgery. After 4 wk of treatment, echocardiography was performed before the rats were euthanized. Animals that received left anterior descending coronary artery ligation demonstrated systolic dysfunction, Smad2 activation, myofibroblasts accumulation, collagen deposition, and myocyte hypertrophy (all P < 0.05). Treatment with GW788388 significantly attenuated systolic dysfunction in the MI animals, together with the attenuation of the activated (phosphorylated) Smad2 (P < 0.01), alpha-smooth muscle actin (P < 0.001), and collagen I (P < 0.05) in the noninfarct zone of MI rats. Cardiomyocyte hypertrophy in MI hearts was also attenuated by ALK5 inhibition (P < 0.05). In brief, treatment with a novel TGF-beta type I receptor inhibitor, GW788388, significantly reduced TGF-beta activity, leading to the attenuation of systolic dysfunction and left ventricular remodeling in an experimental rat model of MI.
引用
收藏
页码:H1415 / H1425
页数:11
相关论文
共 50 条
  • [1] Inhibition of activin receptor-like kinase 5 attenuates Bleomycin-induced pulmonary fibrosis
    Higashiyama, Hiroyuki
    Yoshimoto, Daisuke
    Kaise, Toshihiko
    Matsubara, Shigeki
    Fujiwara, Masatoshi
    Kikkawa, Hideo
    Asano, Satoshi
    Kinoshita, Mine
    EXPERIMENTAL AND MOLECULAR PATHOLOGY, 2007, 83 (01) : 39 - 46
  • [2] Kaempferol attenuates liver fibrosis by inhibiting activin receptor-like kinase 5
    Xu, Taifu
    Huang, Shan
    Huang, Qianrong
    Ming, Zhiyong
    Wang, Min
    Li, Rongrui
    Zhao, Yinnong
    JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 2019, 23 (09) : 6403 - 6410
  • [3] Haplodeficiency of activin receptor-like kinase 4 alleviates myocardial infarction-induced cardiac fibrosis and preserves cardiac function
    Chen, Yi-He
    Wang, Qian
    Li, Chang-Yi
    Hou, Jian-Wen
    Chen, Xiao-Meng
    Zhou, Qing
    Chen, Jie
    Wang, Yue-Peng
    Li, Yi-Gang
    JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, 2017, 105 : 1 - 11
  • [4] Dihydromyricetin attenuates hypertrophic scar formation by targeting activin receptor-like kinase 5
    Ye, Xiaolu
    Pang, Zhiying
    Zhu, Ningwen
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2019, 852 : 58 - 67
  • [5] Partial inhibition of activin receptor-like kinase 4 attenuates pressure overload-induced cardiac fibrosis and improves cardiac function
    Li, Chang-Yi
    Chen, Yi-He
    Wang, Qian
    Hou, Jian-Wen
    Wang, Hong
    Wang, Yue-Peng
    Li, Yi-Gang
    JOURNAL OF HYPERTENSION, 2016, 34 (09) : 1766 - 1777
  • [6] Development of PET tracers for the activin receptor-like kinase 5
    Rotteveel, Lonneke
    Poot, Alex J.
    ten Dijke, Peter
    Bogaard, Harm Jan
    Lammertsma, Adriaan A.
    Windhorst, Albert D.
    JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS, 2017, 60 : S69 - S69
  • [7] Inhibition of transforming growth factor-β via the activin receptor-like kinase-5 inhibitor attenuates pulmonary fibrosis
    Koh, Rhun Yian
    Lim, Chooi Ling
    Uhal, Bruce David
    Abdullah, Maha
    Vidyadaran, Sharmili
    Ho, Coy Choke
    Seow, Heng Fong
    MOLECULAR MEDICINE REPORTS, 2015, 11 (05) : 3808 - 3813
  • [8] Activin receptor-like kinase 4 haplodeficiency alleviates the cardiac inflammation and pacing-induced ventricular arrhythmias after myocardial infarction
    Yang, Yuli
    Wang, Qian
    Cai, Xingxing
    Wei, Zhixing
    Hou, Jianwen
    Fei, Yudong
    Li, Wei
    Li, Yigang
    AGING-US, 2021, 13 (13): : 17473 - 17488
  • [9] Selective inhibition of activin receptor-like kinase 5 signaling blocks profibrotic transforming growth factor β responses in skin fibroblasts
    Mori, Y
    Ishida, W
    Bhattacharyya, S
    Li, YZ
    Platanias, LC
    Varga, J
    ARTHRITIS AND RHEUMATISM, 2004, 50 (12): : 4008 - 4021
  • [10] Activin receptor-like kinase-2 inhibits activin signaling by blocking the binding of activin to its type II receptor
    Renlund, Nina
    O'Neill, Francis H.
    Zhang, LiHua
    Sidis, Yisrael
    Teixeira, Jose
    JOURNAL OF ENDOCRINOLOGY, 2007, 195 (01) : 95 - 103